Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a minimally invasive technique make limb perfusion safer?

NCT ID NCT03376126

Disease control Sponsor: Vastra Gotaland Region Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This trial is testing whether a minimally invasive version of isolated limb perfusion is feasible. Isolated limb perfusion is a procedure that delivers high-dose chemotherapy directly to a limb affected by cancer, but the standard approach requires a large incision. The study will enroll 15 adults scheduled for this treatment and measure how often the minimally invasive approach must be converted to open surgery, as well as how well patients respond and any complications. The goal is to see if this less invasive method can be a viable option.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Minimally-invasive isolated limb perfusion (a surgical technique to deliver chemotherapy directly to a limb)
What this could lead to
If successful, this could make isolated limb perfusion less invasive, potentially reducing recovery time and complications for patients with tumors in a limb.
What could go wrong
This is a small feasibility study, so it may not prove the technique works better than the standard approach. There is also a risk of complications or the need to convert to open surgery during the procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

15 people

The number who actually took part.

Started

Jun 2016

Finished

Jun 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients scheduled for isolated limb perfusion.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. The patient scheduled for treatment with isolated hyperthermic perfusion 2. Age over 18 years. 3. Signed informed consent Exclusion Criteria: 1. Re-perfusion 2. Lymph node metastases 3. Severe atherosclerosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Isolated limb perfusion are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Isolated limb perfusion

Contacts and locations

Locations

  • Sahlgrenska University Hospital

    Gothenburg, 413 45, Sweden